



Health innovation that matters

## **Extension of the Period for Cover of Costs to Cancel Depositary Interests in respect of Intended Cancellation of Ordinary Shares from Listing on the Official List and Admission to Trading on the London Stock Exchange**

23 March 2017

### **LivaNova Plc**

#### **Extension of the Period for Cover of Costs to Cancel Depositary Interests in respect of Intended Cancellation of Ordinary Shares from Listing on the Official List and Admission to Trading on the London Stock Exchange**

LivaNova Plc (“LivaNova”) refers to its announcement of 23 February 2017 announcing its intention to cancel the standard listing of its Shares on the Official List and the admission to trading of its Shares on the main market of the London Stock Exchange with effect from 8:00 a.m. (BST) on 5 April 2017. All capitalised terms used in this announcement that are not defined herein are as defined in the announcement of 23 February 2017.

Shares that are held through the CREST system in the United Kingdom are held in the form of depositary interests, or DIs. The DI Facility will be terminated in connection with the Cancellation. In the announcement of 23 February 2017, LivaNova announced that it would cover all cross-border DI cancellation fees typically charged by Computershare Investor Services PLC in respect of the cancellation of DIs up to and including the close of business on 23 March 2017. LivaNova has now extended this period to up to and including the close of business on 31 March 2017. After that date, any such fees will be payable by the relevant DI holders.

### **Further Information**

Please see the announcement of 23 February 2017 for further information. The announcement is available on LivaNova’s investor relations website at <http://investor.livanova.com>.

### **About LivaNova**

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world.

LivaNova's advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in London and with a presence in more than 100 countries worldwide, the company employs more than 4,500 employees. LivaNova operates as three business franchises: Cardiac Surgery, Neuromodulation and Cardiac Rhythm Management, with operating headquarters in Mirandola (Italy), Houston (U.S.A.) and Clamart (France), respectively.

**For more information, please visit [www.LivaNova.com](http://www.LivaNova.com).**

**Catherine Moroz**

**Company Secretary**

Tel: +44 (0)203 325 0662

Email: [catherine.moroz@livanova.com](mailto:catherine.moroz@livanova.com)

**Karen King**

**VP – Investor Relations**

Tel: +1(281) 228-7441

Email: [karen.king@livanova.com](mailto:karen.king@livanova.com)